These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8764799)

  • 81. Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients.
    Caruso C; Pacente L; Troiano P; Ostacolo C; D'Andrea L; Bartollino S; Costagliola C
    Int Ophthalmol; 2020 Apr; 40(4):823-831. PubMed ID: 31792856
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.
    Mishima HK; Kiuchi Y; Takamatsu M; Rácz P; Bito LZ
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S139-44. PubMed ID: 9154290
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Prostaglandin derivates as ocular hypotensive agents.
    Alm A
    Prog Retin Eye Res; 1998 Jul; 17(3):291-312. PubMed ID: 9695796
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes.
    Lindén C; Alm A
    Acta Ophthalmol Scand; 1997 Aug; 75(4):412-5. PubMed ID: 9374251
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Latanoprost as a new horizon in the medical management of glaucoma.
    Stjernschantz J; Alm A
    Curr Opin Ophthalmol; 1996 Apr; 7(2):11-7. PubMed ID: 10163315
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The pros and cons of different prostanoids in the medical management of glaucoma.
    Susanna R; Medeiros FA
    Curr Opin Ophthalmol; 2001 Apr; 12(2):149-56. PubMed ID: 11224723
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effects of topical administration of 0.005% latanoprost solution on eyes of clinically normal horses.
    Willis AM; Diehl KA; Hoshaw-Woodard S; Kobayashi I; Vitucci MP; Schmall LM
    Am J Vet Res; 2001 Dec; 62(12):1945-51. PubMed ID: 11763186
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Reduction of IOP with latanoprost.
    Hoste AM
    Ophthalmology; 1997 Jun; 104(6):895-7. PubMed ID: 9186420
    [No Abstract]   [Full Text] [Related]  

  • 89. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma.
    Hedner J; Svedmyr N; Lunde H; Mandahl A
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S111-5. PubMed ID: 9154286
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans.
    Nakajima M; Goh Y; Azuma I; Hayaishi O
    Graefes Arch Clin Exp Ophthalmol; 1991; 229(5):411-3. PubMed ID: 1937072
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Efficacy of latanoprost in management of chronic angle closure glaucoma.
    Kumar S; Malik A; Singh M; Sood S
    Nepal J Ophthalmol; 2009; 1(1):32-6. PubMed ID: 21141019
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prostaglandin analogs in the treatment of glaucoma.
    Hejkal TW; Camras CB
    Semin Ophthalmol; 1999 Sep; 14(3):114-23. PubMed ID: 10790575
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.
    Ciolino JB; Ross AE; Tulsan R; Watts AC; Wang RF; Zurakowski D; Serle JB; Kohane DS
    Ophthalmology; 2016 Oct; 123(10):2085-92. PubMed ID: 27586444
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
    Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
    Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Trans-conjunctival aqueous humor outflow in glaucomatous patients treated with prostaglandin analogues: an in vivo confocal microscopy study.
    Mastropasqua R; Fasanella V; Pedrotti E; Lanzini M; Di Staso S; Mastropasqua L; Agnifili L
    Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1469-76. PubMed ID: 24867312
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect.
    Bito LZ
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S1-14. PubMed ID: 9154271
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Therapeutic potential of prostaglandin analogues in glaucoma.
    Lindén C
    Expert Opin Investig Drugs; 2001 Apr; 10(4):679-94. PubMed ID: 11281818
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Effect of latanoprost on ocular hemodynamics and contrast sensitivity].
    Kuba GB; Kurnatowski-Billion M; Neuser AM; Austermann P
    Ophthalmologe; 2001 Jun; 98(6):535-40. PubMed ID: 11450476
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.
    Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS
    PLoS One; 2011; 6(9):e24513. PubMed ID: 21931735
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles.
    Halder A; Khopade AJ
    Curr Eye Res; 2021 Jul; 46(7):1031-1037. PubMed ID: 33719796
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.